Rheumatoid Arthritis – Landscape & Forecast – Disease Landscape & Forecast
Although the tumor necrosis factor-alpha (TNF-α) inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) patients refractory to conventional DMARD treatment (the first-line standard of care), the RA drug market boasts a variety of targeted agents from many drug classes, all competing largely for shares of the TNF-refractory population. The continued launch of biosimilars across the major markets will make the crowded therapy market more competitive. Increasing safety concerns about the JAK inhibitor class have pushed use of these agents to follow use of TNF-α inhibitors, primarily impacting the uptake of Xeljanz in the G7 markets. Although the late-phase pipeline is relatively sparse, the sheer number of biologics and targeted oral therapies available for RA ensures that marketers face fierce competition and increasing challenges to gain and maintain market share.
Questions answered
- What are physicians’ preferred TNF-α inhibitors, and what factors influence this perception? Given the increasingly fragmented RA market, how likely are physicians to cycle through multiple anti-TNF agents before progressing to a novel mechanism of action?
- What are physicians’ perceptions of the currently marketed non-TNF-α inhibitor biologics and oral JAK inhibitors, and where do these agents fit in their current treatment approach? Which of these agents has been/will be the most successful in targeting the TNF-refractory patient segment? How have the new safety warnings regarding JAK inhibitors affected physicians’ prescribing of these agents in the RA treatment algorithm?
- How will the entry of additional novel oral therapies affect the RA treatment algorithm? In which patient segments and treatment lines will these therapies most likely be used? How will biosimilars affect sales and patient share of current RA agents and the uptake of emerging therapies?
Content highlights
Markets covered: United States, EU5, Japan.
Primary research: 30 country-specific interviews with thought-leading rheumatologists.
Epidemiology: Number of total, diagnosed, and drug-treated prevalent cases of RA by country; number of diagnosed prevalent cases of RA by severity.
Emerging therapies: Phase III/PR: 1 drug; Phase II: 8 drugs; coverage of select early-phase products.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will feature continual updates to provide timely insights and analyses as meaningful indication-specific news and events unfold. Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Rheumatoid Arthritis - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Rheumatoid arthritis - key findings - January 2023
- Key updates
- May 2023
- January 2023
- Q4 2022
- December 2022
- November 2022
- October 2022
- Q3 2022
- July 2022
- Q2 2022
- June 2022
- May 2022
- April 2022
- Market outlook
- Key findings
- Market share of drug classes for rheumatoid arthritis: 2021
- Market share of drug classes for rheumatoid arthritis: 2031
- Rheumatoid arthritis SWOT analysis
- Market drivers and constraints
- What factors are driving the market for rheumatoid arthritis?
- What factors are constraining the market for rheumatoid arthritis?
- Major-market patient shares of biologics and JAK inhibitors in rheumatoid arthritis: 2021-2031
- Drug-class-specific trends
- TNF-alpha inhibitors
- Major-market sales of TNF-alpha inhibitors for rheumatoid arthritis: 2021-2031
- Major-market brand and biosimilar patient share for TNF-alpha inhibitors in rheumatoid arthritis: 2021-2031
- Major-market patient share of abatacept for rheumatoid arthritis (SC, IV, and total): 2021-2031
- Major-market brand and biosimilar patient share and total sales for rituximab in rheumatoid arthritis: 2021-2031
- Major-market sales and patient share of IL-6 inhibitors for rheumatoid arthritis: 2021-2031
- Major-market patient share of JAK inhibitors for rheumatoid arthritis: 2021-2031
- Major-market sales of JAK inhibitors for rheumatoid arthritis: 2021-2031
- Key findings
- Forecast
- Market forecast assumptions
- Market forecast dashboard
- Etiology and pathophysiology
- Disease Overview
- Disease overview
- Etiology
- Genetic factors
- Environmental risk factors
- Pathophysiology
- Disease progression
- Disease progression in rheumatoid arthritis
- Pathological changes in the joints of patients with rheumatoid arthritis
- Adaptive and innate immune responses in disease pathogenesis
- Key pathways and drug targets
- Select drug targets in rheumatoid arthritis
- Select cytokines involved in the pathogenesis of rheumatoid arthritis
- Other inflammatory mediators involved in the pathogenesis of rheumatoid arthritis
- Disease Overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition
- Methods
- Sources used for total prevalent cases of rheumatoid arthritis
- Number of total cases of rheumatoid arthritis in the major pharmaceutical markets: 2021-2031
- Number of diagnosed prevalent cases of rheumatoid arthritis in the major pharmaceutical markets: 2021-2031 (thousands)
- Disease definition
- Methods
- Sources used for diagnosed prevalent cases by severity in rheumatoid arthritis
- Diagnosed prevalent cases of rheumatoid arthritis by severity: 2021-2031
- Number of drug-treated prevalent cases of rheumatoid arthritis in the major pharmaceutical markets: 2021-2031 (thousands)
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for rheumatoid arthritis
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for rheumatoid arthritis
- Current treatments used for rheumatoid arthritis
- Market events impacting the use of key current therapies in rheumatoid arthritis
- Advantages and disadvantages of etanercept
- Advantages and disadvantages of infliximab
- Expert insight: infliximab
- Advantages and disadvantages of adalimumab
- Advantages and disadvantages of Simponi
- Expert insight: Simponi
- Advantages and disadvantages of Cimzia
- Expert insight: Cimzia
- Ozoralizumab (Nanozora)
- Advantages and disadvantages of Nanozora
- Advantages and disadvantages of Orencia
- Expert insight: Orencia
- Advantages and disadvantages of rituximab
- Expert insight: rituximab
- Advantages and disadvantages of Actemra / RoActemra
- Expert insight: Actemra / RoActemra
- Advantages and disadvantages of Kevzara
- Expert insight: Kevzara
- Advantages and disadvantages of Xeljanz
- Expert insight: Xeljanz
- Olumiant
- Advantages and disadvantages of Olumiant
- Expert insight: Olumiant
- Rinvoq
- Advantages and disadvantages of Rinvoq
- Expert insight: Rinvoq
- Jyseleca
- Advantages and disadvantages of Jyseleca
- Expert insight: Jyseleca
- Advantages and disadvantages of Smyraf
- Expert insight: Smyraf
- Advantages and disadvantages of Pralia
- Expert insight: Pralia
- Medical practice
- Overview
- Factors influencing drug selection in rheumatoid arthritis
- Treatment decision tree for rheumatoid arthritis: United States
- Treatment decision tree for rheumatoid arthritis: Europe
- Treatment decision tree for rheumatoid arthritis: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in rheumatoid arthritis
- Top unmet needs in rheumatoid arthritis: current and future attainment
- Drug pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging therapies
- Key findings
- Key emerging therapy
- Estimated launch dates of key emerging therapy for the treatment of rheumatoid arthritis
- Olokizumab profile
- Analysis of the clinical development program for olokizumab
- Expert insight: olokizumab
- Expectations for launch and sales opportunity of olokizumab in rheumatoid arthritis
- Early-phase pipeline analysis
- Select compounds in early-phase development for rheumatoid arthritis
- Key discontinuations and failures in rheumatoid arthritis
- Key discontinuations and failures
- Key findings
- Access & reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in rheumatoid arthritis: United States
- General reimbursement environment: United States
- Key market access considerations in rheumatoid arthritis: EU5
- General reimbursement environment: EU5
- Key market access considerations in rheumatoid arthritis: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Rheumatoid arthritis bibliography
- Key findings
Sheema Kher, M.Pharm., Associate Healthcare Research & Data Analyst, Immune and Inflammation. Ms. Kher has much experience in the U.S. market access and payer landscape and has analyzed formulary and payer restrictions in multiple therapy areas for diverse lines of business, including commercial, HIX, managed Medicaid, state Medicaid, and Medicare. She holds a master’s degree in drug regulatory affairs from Amity University in Noida.
Aishwarya S. Ambat, M.P.H., Epidemiologist , Epidemiology. She received her M.P.H. from the Manipal Academy of Higher Education in India and holds a bachelor’s degree in physiotherapy. Her areas of interest are rheumatic disease and cancer epidemiology.